June 4, 2018 The anti–PD-1 antibody pembrolizumab previously demonstrated superior overall survival (OS) in patients with advanced melanoma compared with ipilimumab in the phase III, multicenter randomized KEYNOTE-006 trial (NCT01866319).1 During the Melanoma/Skin Cancers Oral Abstract Session, held June 4, Georgina V. Long, MD, PhD, FRACP, of the Melanoma Institute Australia, University of Sydney,...
Pro zobrazení tohoto obsahu je třeba být přihlášen.